Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Market Size, Share, Competitive Landscape, Dynamics, Trends, Challenges, and Growth Opportunities, 2022 - 2030

The global irritable bowel syndrome treatment market size was valued at $1,634.2 million in 2023 and is projected to reach $3,867.6 million by 2030, growing at a CAGR of 13.1% from 2023 to 2030. Increasing prevalence, improved awareness, and diagnosis, expanding treatment options, expanding treatment options, biological therapies, growing healthcare expenditure, rising patient preference for non-invasive treatments, and a supportive regulatory environment are some of the growth drivers boosting the growth of the irritable bowel syndrome market. Further, the ongoing research and clinical trials focusing on understanding the pathophysiology of IBS and exploring potential therapeutic targets contributed to the growth of the IBS market.

Market Dynamics and Trends

Irritable bowel syndrome is a common gastrointestinal disorder, and its prevalence was rising worldwide. Factors such as changing dietary habits, stress, and sedentary lifestyles contributed to the increasing number of IBS cases, leading to higher demand for treatments. Irritable bowel syndrome is a common gastrointestinal disorder, and its prevalence was rising worldwide. Factors such as changing dietary habits, stress, and sedentary lifestyles contributed to the increasing number of IBS cases, leading to higher demand for treatments.

Pharmaceutical companies were investing in research and development to bring novel IBS treatments to the market. This included new drugs targeting specific symptoms of IBS, such as abdominal pain, bloating, and altered bowel habits. The development of biological therapies, such as targeted antibodies, aimed at modulating the immune response and gut microbiome, offered new treatment options for patients with severe or refractory IBS symptoms.

The overall increase in healthcare expenditure in many countries allowed patients to access better medical facilities, including specialized treatments for chronic conditions like IBS. As patients became more conscious of the potential side effects of traditional treatments, there was a shift towards non-invasive or natural therapies, such as dietary changes, probiotics, and lifestyle modifications. Supportive regulatory policies in some regions facilitated the approval and commercialization of new IBS treatments, encouraging further investment in the market.

Market Segmentation

Across irritable bowel syndrome treatment market, the segments covered are by type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. Based on product, the market is bifurcated into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. By end user, the market is bifurcated into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. By region, the irritable bowel syndrome treatment market is analyzed across North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

The scope of the report further includes the market segmentation by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. The IBS with diarrhea (IBS-D) segment acquired the largest irritable bowel syndrome treatment market share in 2018. Furthermore, this segment is also expected to experience growth at the fastest rate during the forecast period, owing to an increase in the prevalence of gastrointestinal diseases such as constipation and diarrhea due to changes in lifestyles, an increase in the geriatric population, surge in uptake of drugs such as linaclotide and lubiprostone, and rise in patient awareness toward the treatment of irritable bowel syndrome.

Key Market Players – Competitive Landscape

Some of the key players in the irritable bowel syndrome treatment market are Abbott Laboratories, AstraZeneca plc, Ardelyx Inc., Johnson & Johnson (McNeil Consumer Healthcare), GlaxoSmithKline Plc, Allergan plc, Sebela Pharmaceuticals Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., and Novartis AG, among others.

Market Segmentation of the Global Irritable Bowel Syndrome Treatment Market